Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment
Related Experiment Video
Updated: Feb 23, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Paul Zarogoulidis1, Evaggelia Athanasiou2, Theodora Tsiouda1
1Pulmonary-Oncology Unit, "Theageneio" Anticancer Hospital, Thessaloniki, Greece.
Abstract:
In this decade a "bloom" of novel therapies has been observed for non-small cell lung cancer. We have new tools for the diagnosis of lung cancer and also we can re-biospy easier than before in different lesions and obtain tissue samples in order to investigate whether a patient can receive new targeted therapies. Immunotherapy has been well established previously for other forms of cancer, and nowadays it is also available for lung cancer. There are two immunotherapies for now nivolumab and pembrolizumab which can be administered as second line treatment, the second can also be administered as first-line if there is a programmed death-ligand 1 ≥50% expression.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...

